Skip to main content

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency
Skip to results

103 updates

Skip to results
103 updates
About Psychiatry
  • Lorazepam: reduction of recommended maximum daily dose

    Maximum dose of lorazepam for short term, symptomatic treatment is 4 mg per day for severe, disabling anxiety, and 2 mg per day for severe, disabling insomnia

    • Therapeutic area: Psychiatry
    • Published:
  • Pabrinex: allergic reactions

    Rare occurrence of serious allergic reactions should not preclude use of parenteral thiamine in patients who need treatment by this route of administration.

    • Therapeutic area: Nutrition and dietetics and 1 others
    • Published:
  • Duloxetine: marketed as Cymbalta▼ and Yentreve▼ for different disorders

    Patients should be assessed regularly due to reported cases of suicidal ideation and suicidal behaviour during treatment with duloxetine or shortly after stopping treatment.

    • Therapeutic area: Endocrinology, diabetology and metabolism and 2 others
    • Published: